- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00552058
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease
2018년 7월 10일 업데이트: UCB Pharma
Phase IIIb, Multinational, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-Tumor Necrosis Factor(TNF)-Alpha Monoclonal Antibody, Administered in Subjects With Moderately to Severely Active Crohn's Disease.
The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index (CDAI) score at Week 6.
연구 개요
연구 유형
중재적
등록 (실제)
439
단계
- 3단계
확장된 액세스
사용 가능 임상시험 외.
확장 액세스 기록을 참조하세요.
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
-
Auckland, 뉴질랜드
-
Christchurch, 뉴질랜드
-
Hamilton, 뉴질랜드
-
-
Auckland
-
Milford, Auckland, 뉴질랜드
-
-
Wellington
-
Newton, Wellington, 뉴질랜드
-
-
-
-
-
Berlin, 독일
-
Frankfurt, 독일
-
Freiburg, 독일
-
Homburg, 독일
-
Jena, 독일
-
Kiel, 독일
-
Munchen, 독일
-
Ulm, 독일
-
Wilhelmshaven, 독일
-
-
-
-
-
Riga, 라트비아
-
Valmiera, 라트비아
-
-
-
-
-
Kazan, 러시아 연방
-
Moscow, 러시아 연방
-
St. Petersburg, 러시아 연방
-
-
-
-
-
Bucharest, 루마니아
-
Cluj Napoca, 루마니아
-
Constanta, 루마니아
-
-
-
-
Alabama
-
Pell City, Alabama, 미국
-
-
Colorado
-
Colorado Springs, Colorado, 미국
-
Lakewood, Colorado, 미국
-
Littleton, Colorado, 미국
-
-
Florida
-
Hollywood, Florida, 미국
-
Jacksonville, Florida, 미국
-
New Port Richey, Florida, 미국
-
Winter Park, Florida, 미국
-
-
Illinois
-
Chicago, Illinois, 미국
-
-
Kentucky
-
Louisville, Kentucky, 미국
-
-
Louisiana
-
Metairie, Louisiana, 미국
-
Monroe, Louisiana, 미국
-
-
Maryland
-
Annapolis, Maryland, 미국
-
Towson, Maryland, 미국
-
-
Michigan
-
Chesterfield, Michigan, 미국
-
West Bloomfield, Michigan, 미국
-
-
Minnesota
-
Rochester, Minnesota, 미국
-
-
North Carolina
-
Raleigh, North Carolina, 미국
-
-
Ohio
-
Cincinnati, Ohio, 미국
-
Cleveland, Ohio, 미국
-
-
Pennsylvania
-
Lancaster, Pennsylvania, 미국
-
-
Tennessee
-
Germantown, Tennessee, 미국
-
-
Virginia
-
Norfolk, Virginia, 미국
-
-
Washington
-
Seattle, Washington, 미국
-
-
-
-
-
Bonheiden, 벨기에
-
Brussels, 벨기에
-
Gent, 벨기에
-
Leuven, 벨기에
-
Liege, 벨기에
-
Roeselare, 벨기에
-
-
-
-
-
Curitiba, 브라질
-
Goiania, 브라질
-
Porto Alegre, 브라질
-
Rio de Janeiro, 브라질
-
Santo-Andre, 브라질
-
Santos, 브라질
-
Sao Paulo, 브라질
-
-
MG
-
Belo-Horizonte, MG, 브라질
-
-
-
-
-
Tallin, 에스토니아
-
Tartu, 에스토니아
-
-
-
-
-
Wien, 오스트리아
-
-
-
-
-
Dniepropetrovsk, 우크라이나
-
Donetsk, 우크라이나
-
Kiev, 우크라이나
-
Kyiv, 우크라이나
-
Lviv, 우크라이나
-
Simferopol, 우크라이나
-
-
-
-
-
Beer Sheva, 이스라엘
-
Haifa, 이스라엘
-
Holon, 이스라엘
-
Jerusalem, 이스라엘
-
Kfar Saba, 이스라엘
-
Petha Tikva, 이스라엘
-
Rehovot, 이스라엘
-
Tel Aviv, 이스라엘
-
Zerifin, 이스라엘
-
-
-
-
-
Bologna, 이탈리아
-
Padova, 이탈리아
-
Roma, 이탈리아
-
-
-
-
-
Hradec Kralove, 체코
-
Hradek Kralove, 체코
-
Praha 7, 체코
-
Usti Nad Orlici, 체코
-
Zlin, 체코
-
-
-
-
-
Santiago, 칠레
-
Vina del Mar, 칠레
-
-
-
-
-
Calgary, 캐나다
-
-
Alberta
-
Edmonton, Alberta, 캐나다
-
-
British Columbia
-
Kelowna, British Columbia, 캐나다
-
-
Manitoba
-
Winnipeg, Manitoba, 캐나다
-
-
Ontario
-
Hamilton, Ontario, 캐나다
-
Kingston, Ontario, 캐나다
-
London, Ontario, 캐나다
-
Toronto, Ontario, 캐나다
-
-
-
-
-
Czestochowa, 폴란드
-
Lodz, 폴란드
-
Warszawa, 폴란드
-
Wroclaw, 폴란드
-
-
-
-
-
Mikkeli, 핀란드
-
-
-
-
-
Budapest, 헝가리
-
Gyor, 헝가리
-
Nagykanizsa, 헝가리
-
Szeged, 헝가리
-
Szombathely, 헝가리
-
-
-
-
-
Adelaide, 호주
-
Bankstown, 호주
-
Clayton, 호주
-
Fitzroy, 호주
-
Fremantle, 호주
-
Garran, 호주
-
-
New South Wales
-
Concord, New South Wales, 호주
-
-
Victoria
-
Box Hill, Victoria, 호주
-
Footscray, Victoria, 호주
-
Parkville, Victoria, 호주
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- male/female
- 18 - 75 years inclusive
- diagnosis of Crohn's disease confirmed
- moderate to severe disease activity (Crohn's Disease Activity Index (CDAI) 225 - 450)
- no previous treatment with anti-tumor necrosis factor (anti-TNF) medications
Exclusion Criteria:
- previous participation in a certolizumab pegol study
- general exclusion criteria as common for studies in this indication
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Certolizumab pegol
Certolizumab pegol 400 mg for subcutaneous (sc) injection
|
Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
다른 이름들:
|
|
위약 비교기: Placebo
Placebo, saline solution for sc injection
|
Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Subjects in Clinical Remission at Week 6
기간: Week 6
|
The percentage of subjects in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Subjects Achieving a Clinical Response at Week 6
기간: Week 0, Week 6
|
The percentage of subjects achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 6
기간: Week 6
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 6 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 6
|
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 6
기간: Week 0 to Week 6
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 6. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0 to Week 6
|
|
Change in Harvey Bradshaw Index (HBI) Score From Week 0 to Week 6
기간: Week 0 to Week 6
|
The change in Harvey Bradshaw Index (HBI) score from Week 0 to Week 6. HBI score consists of clinical parameters of general well-being (0 to 4), abdominal pain (0 to 3), number of liquid stools per day, abdominal mass (0 to 3), and complications (score 1 per item).
The first three items are scored for the previous day.
Lower scores indicated better well being.
|
Week 0 to Week 6
|
|
Percentage of Subjects in Clinical Remission at Week 2
기간: Week 2
|
The percentage of subjects in clinical remission at Week 2 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 2
|
|
Percentage of Subjects in Clinical Remission at Week 4
기간: Week 4
|
The percentage of subjects in clinical remission at Week 4 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 4
|
|
Percentage of Subjects Achieving a Clinical Response at Week 2
기간: Week 0, Week 2
|
The percentage of subjects achieving a clinical response at Week 2 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 2
|
|
Percentage of Subjects Achieving a Clinical Response at Week 4
기간: Week 0, Week 4
|
The percentage of subjects achieving a clinical response at Week 4 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 4
|
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 2
기간: Week 0 to Week 2
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 2. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0 to Week 2
|
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 4
기간: Week 0, Week 4
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 4. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 4
|
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 2
기간: Week 2
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 2 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 2
|
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 4
기간: Week 4
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 4 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 4
|
|
Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6
기간: Week 6
|
The percentage of subjects in the subgroup with less than 10 mg/L of C-reactive Protein (CRP) at Entry who are in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
|
Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6
기간: Week 6
|
The percentage of subjects in the subgroup with 10 mg/L or greater C-reactive Protein (CRP) at Entry in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
|
Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
기간: Week 0, Week 6
|
The percentage of subjects in the subgroup with less than 10 mg/L C-reactive Protein (CRP) at Entry achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
|
Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
기간: Week 0, Week 6
|
The percentage of subjects in the subgroup with 10 mg/L or greater C-reactive Protein (CRP) at Entry achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
일반 간행물
- Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011 Aug;9(8):670-678.e3. doi: 10.1016/j.cgh.2011.04.031. Epub 2011 May 13.
- Sandborn WJ, Melmed GY, McGovern DP, Loftus EV Jr, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther. 2015 Aug;42(3):330-42. doi: 10.1111/apt.13251. Epub 2015 Jun 1.
- Sandborn WJ, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, Kayhan C, Pierre-Louis B, Schreiber S, Lichtenstein GR. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014 Oct;40(8):903-16. doi: 10.1111/apt.12930. Epub 2014 Aug 22.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2008년 3월 1일
기본 완료 (실제)
2009년 10월 1일
연구 완료 (실제)
2009년 11월 1일
연구 등록 날짜
최초 제출
2007년 10월 18일
QC 기준을 충족하는 최초 제출
2007년 10월 31일
처음 게시됨 (추정)
2007년 11월 1일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2018년 8월 9일
QC 기준을 충족하는 마지막 업데이트 제출
2018년 7월 10일
마지막으로 확인됨
2011년 10월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .